[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overweightobesity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overweightobesity":56},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,42,73,109,139,163,200,222,253,281],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100635294","phase-1-drug-drug-interaction-study-of-zt002-injection-in-overweight-and-obese-participants-100635294",false,"NCT07550816","Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants","A Drug-drug Interaction Study to Evaluate the Impact of Multiple Subcutaneous Injections of ZT002 on the Pharmacokinetics of Metformin, Warfarin, Rosuvastatin and Digoxin in Overweight and Obese Participants","Inclusion Criteria:\n\n* Age between 18 - 45 years (both inclusive) at the time of signing of the informed consent;\n* Male (body weight \\>60.0 kg) or female (body weight \\>55.0 kg). Body mass index (BMI) 24.0 - 35.0 kg\u002Fm²(both inclusive);\n* Considered to be generally healthy based on physical examination, and the results of vital signs, 12-lead electrocardiogram and clinical laboratory tests (hematology, urinalysis, chemistry, coagulation), as judged by the investigator.\n\nExclusion Criteria:\n\n* Clinically significant diseases detected within 6 months before screening (including but not limited to neurological, psychiatric, cardiovascular, endocrine, gastrointestinal, respiratory, urinary, hematological, immunological diseases), judged by the investigator as possible to influence the study result or introduce safety risk to study drug administration;\n* History of dysphagia or any gastrointestinal tract disease that affects drug absorption;\n* Known hypersensitivity (asthma, hypersensitivity to GLP-1 receptor agonists or excipients), or known hypersensitivity to ZT002 injection;\n* History of inspirational pneumonia within 5 years before screening;\n* Medical history of hypoglycemia within 6 months before screening;\n* History of acute or chronic pancreatitis;\n* Cholelithiasis ≤ 1 cm, or history of cholecystitis or other symptomatic gallbladder disease, with the exception of cholecystectomy \\> 6 months prior to screening;\n* History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2;\n* Glycated hemoglobin (HbA1c) ≥ 6.5% or fasting plasma glucose ≥ 7.0 mmol\u002FL at screening;\n* Aspartate aminotransferase ≥ 2 × upper limit of normal (ULN), Alanine aminotransferase ≥ 2 × ULN,\n* Alkaline phosphatase total bilirubin ≥ 1.5 × ULN;\n* Calcitonin above ULN at screening;\n* Thyroid stimulating hormone (TSH) \\\u003C 0.4 or \\>6.0 mIU\u002FL;\n* Use of hypoglycemic drugs (e.g. insulin, insulin secretagogues, thiazolidinedione, sodium-dependent glucose transporters 2 inhibitors \\[SGLT2i\\], dipeptidyl peptidase 4 inhibitor \\[DPP-4i\\], glucagon-like peptide-1 receptor agonist \\[GLP-1RA\\], metformin, α-glucosidase inhibitor) within 3 months before screening;\n* Use of prescription drugs, over-the-counter drugs, dietary supplements, vitamins, or herbal medicines (excluding topical eye\u002Fnose drops and external use on the skin without systemic exposure risk) within 2 weeks before screening.\n\nExclusion criteria only applicable to Cohort 1:\n\n* History that increases risk of bleeding, e.g. aneurysm, aortic dissection, cerebral vascular malformation, acute gastritis, gastric or duodenal ulcer; hemorrhoid bleeding within 1 month prior to screening;\n* Hypersensitivity to metformin or warfarin;\n* Prothrombin time (PT), international normalized ratio (INR) or activated partial thromboplastin time (APTT) above ULN and judged as clinically significant by investigator;\n* Platelet \\\u003C 100x109\u002FL;\n* Ventricular rate \\\u003C 50 or \\> 100 bpm, second or third degree of atrioventricular block, left bundle branch block, complete right bundle branch block, or QT interval corrected by Fridericia's formula (QTcF) \\> 450 ms, or other abnormal electrocardiogram of clinical significance.\n\nExclusion criteria only applicable to Cohort 2:\n\n* History of unexplained myalgia or myasthenia, or diagnosed with rhabdomyolysis;\n* Hypersensitivity to rosuvastatin or digoxin;\n* Unexplained creatine kinase above ULN;\n* Serum potassium out of reference range;\n* Ventricular rate \\\u003C 55 or \\> 100 bpm, atrial fibrillation, atrioventricular block of any degree, preexcitation syndrome, left bundle branch block, complete right bundle branch block, or QT interval corrected by Fridericia's formula (QTcF) \\> 450 ms, or other abnormal electrocardiogram of clinical significance.",true,"ALL","18 Years","45 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","ZT002 is an ultralong-acting glucagon-like peptide-1. This open-label, fixed sequence, two-period crossover drug-drug interaction study is designed to evaluate the impact of ZT002 on the PK of metformin, warfarin, rosuvastatin and digoxin. The study will include obese and overweight but otherwise healthy participants aged 18 - 45.\n\nThe study consists of two cohorts. Each participant can only join one of the cohorts.\n\nCohort 1 evaluates the impact of ZT002 on the PK of metformin at steady state and on the PK of a single dose of warfarin. Participants are screened within 2 weeks before study drug administration. In the first period, metformin is given twice daily for 3.5 days and warfarin is given as a single dose without ZT002. In the second period, metformin and warfarin are given, following the same dose and regimen as in the first period, concomitantly with ZT002, which reaches steady state by up-titration. The participants will be followed up for 6 weeks after the last dose of ZT002.\n\nCohort 2 evaluates the impact of ZT002 on the PK of single doses of rosuvastatin and digoxin. Participants are screened within 2 weeks before study drug administration. In the first period, rosuvastatin and digoxin are given as single doses without ZT002. In the second period, rosuvastatin and digoxin are given, following the same dose and regimen as in the first period, concomitantly with ZT002, which reaches steady state by up-titration. The participants will be followed up for 6 weeks after the last dose of ZT002.",[28],"Overweight,Obesity","RECRUITING","2026-06-18",{"date":32,"type":33},"2026-06-22","ACTUAL",{"date":35,"type":33},"2026-05-27",{"date":37,"type":22},"2027-03-26",{"name":39,"class":40},"Beijing QL Biopharmaceutical Co.,Ltd","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":41},"100564314","exercise-effects-on-the-neurobiology-underlying-stress-related-eating-behaviors-in-veterans-100564314","NCT06627569","Exercise Effects on the Neurobiology Underlying Stress-related Eating Behaviors in Veterans","Exercise Effects on the Neurobiology Underlying Stress-Related Eating Behaviors in Veterans","Inclusion Criteria:\n\n* Veterans 18-75 years old\n* BMI of 25 or greater\n* Physically inactive\n* Able to attend study visits in person in Aurora, CO\n\nExclusion Criteria:\n\n* Currently pregnant\n* History of bariatric surgery\n* Current eating disorder\n* Current treatment with appetite-altering medications (e.g., GLP-1 agonists)\n* Contraindication to MRI (weight \\> 500 lbs; claustrophobia; metal or electronic devices in the body)\n* Cardiovascular disease, chronic kidney disease, pulmonary disease, or diabetes\n* Unable to exercise due to cardiac, pulmonary, neurologic, or orthopedic reasons","75 Years",{"count":51,"type":22},132,[53],"NA","The purpose of this study is to learn more about how common lifestyle interventions, such as exercise, affect how our brains respond to performing thinking tasks and to viewing pictures of foods and various other objects. The investigators are also interested in how changes in hormones that might be different in men and women could affect how lifestyle interventions change these brain responses.",[56,57],"Overweight\u002FObesity","Stress",[59,60,57,61],"Overweight","Obesity","Eating","NOT_YET_RECRUITING","2026-06-11",{"date":65,"type":33},"2026-06-15",{"date":67,"type":22},"2026-07-01",{"date":69,"type":22},"2030-08-30",{"name":71,"class":72},"VA Office of Research and Development","FED",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":41},"100631827","phase-2-mots-c-for-improving-insulin-sensitivity-in-adults-with-prediabetes-and-overweightobesity-100631827","NCT07505745","MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight\u002FObesity","A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c (a Mitochondrial-Derived Peptide) in Adults With Prediabetes and Overweight\u002FObesity","MOTS-MET","Inclusion Criteria:\n\n* Age 18 to 65 years at the time of consent.\n* Body mass index (BMI) 27.0 to 40.0 kg\u002Fm\\^2.\n* Prediabetes documented at screening by any of the following: (a) HbA1c 5.7% to 6.4%; (b) fasting plasma glucose 100 to 125 mg\u002FdL; or (c) 2-hour plasma glucose 140 to 199 mg\u002FdL during a 75 g OGTT.\n* Stable body weight (less than 5% change) for at least 3 months prior to screening.\n* Willingness to maintain stable diet and physical activity patterns during the 12-week treatment period.\n* For participants of childbearing potential: agreement to use highly effective contraception for the study duration and for a protocol-specified period after last dose.\n* Ability to understand and sign informed consent.\n\nExclusion Criteria:\n\n* Diabetes mellitus (e.g., HbA1c 6.5% or higher, fasting plasma glucose 126 mg\u002FdL or higher, or 2-hour glucose 200 mg\u002FdL or higher at screening).\n* Use of glucose-lowering medications (including metformin, GLP-1 receptor agonists, SGLT2 inhibitors) within 3 months prior to screening.\n* History of bariatric surgery or planned weight-loss surgery during the study period.\n* Clinically significant cardiovascular disease within 6 months (e.g., myocardial infarction, stroke, unstable angina) or uncontrolled hypertension.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m\\^2, clinically significant hepatic disease, or ALT\u002FAST \\> 2.5x upper limit of normal at screening.\n* Active malignancy requiring treatment (except adequately treated non-melanoma skin cancer).\n* Pregnant, breastfeeding, or planning pregnancy during the study period.\n* Known hypersensitivity to peptide therapeutics or any component of the investigational product formulation.\n* Any condition that, in the investigator's judgment, would interfere with study participation or interpretation of results (e.g., inability to comply with study procedures).","65 Years",{"count":83,"type":22},120,[85],"PHASE2","This Phase 2a study evaluates whether 12 weeks of treatment with investigational MOTS-c improves insulin sensitivity compared with placebo in adults with prediabetes and overweight\u002Fobesity.\n\nParticipants are randomized 1:1 to MOTS-c or placebo, receive standardized lifestyle counseling, and are followed for safety through Week 16.",[88,89,56],"Prediabetes","Insulin Resistance",[91,92,93,94,95,96,97,98,99],"MOTS-c","mitochondrial-derived peptide","MDP","insulin sensitivity","AMPK","prediabetes","metabolic syndrome","OGTT","HbA1c","2026-03-26",{"date":102,"type":33},"2026-04-01",{"date":104,"type":33},"2026-02-02",{"date":106,"type":22},"2028-05-17",{"name":108,"class":40},"Hudson Biotech",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":19,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":41},"100625865","snacking-effects-on-the-brain-response-to-foods-and-satiety-during-dieting-100625865","NCT07428187","Snacking Effects on the Brain Response to Foods and Satiety During Dieting","Inclusion Criteria:\n\n* 25-45 years old\n* BMI at least 27 kg\u002Fm2\n* Comfortable completing a weight-loss intervention\\\\\n* Willing to consume a daily snack of either walnuts or pretzels\n\nExclusion Criteria:\n\n* Nut or wheat allergy\n* History of bariatric surgery\n* Current eating disorder\n* Current illicit substance use\n* Current pregnancy, lactation (or less than 3 months after stopping lactation), or less than 6 months postpartum\n* Uncontrolled hypertension (\\>160\u002F100 mmHg)\n* Significant endocrine\u002Fmetabolic disease kidney disease, liver disease, or blood disease that would be anticipated to affect study results\n* Taking injectable medications, sulfonylureas, or meglitinides for diabetes treatment\n* Taking weight-loss medications, or steroids within \\~3 months prior to study participation (e.g., GLP-1 receptor agonists)\n* Significant mental health changes within \\~3 months prior to study participation (e.g., medication adjustments, new psychiatric diagnoses, hospitalization relating to mental health concerns)\n* Neurological illnesses or injury that would be anticipated to affect MRI data\n* Weight change greater than 10% within 3 months prior to study participation\n* Currently participating in another weight-loss study\n* Not comfortable eating the study-provided meals (with allowances for dietary preferences) and\u002For following a highly restrictive diet (e.g., vegan)\n* MRI-specific exclusion criteria (e.g., metal in the body, weight \\>500 lbs","25 Years",{"count":117,"type":22},70,[53],"This study plans to learn more about how different types of snacks may affect brain processes relating to eating behaviors during a diet intervention.",[56],[122,123,59,60,124,125,126,61,127,128],"Dieting","Weight loss","Food","Neuroimaging","Body weight","Brain","Magnetic resonance imaging","2026-03-19",{"date":131,"type":33},"2026-03-23",{"date":133,"type":33},"2026-03-05",{"date":135,"type":22},"2028-03-31",{"name":137,"class":138},"University of Colorado, Denver","OTHER",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":16,"sex":17,"minAge":115,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":41},"100628378","effects-of-cranberry-on-gut-and-metabolic-health-100628378","NCT07460856","Effects of Cranberry on Gut and Metabolic Health","CRANOS","Inclusion Criteria:\n\n* body mass index between 25 and 40 kg\u002Fm2\n* at least one of the following criteria: fasting plasma insulin \\>60 pmol\u002FL, fasting glycemia between 5.5 and 6.9 mmol\u002FL, glycated hemoglobin (HbA1c) level of 5.7- 6.4% and\u002For fasting triglyceride \\>1.35 mmol\u002FL.\n\nExclusion Criteria:\n\n* to have aversion to cranberry products\n* regularly drinking alcohol (\\>2 glasses\u002Fday)\n* having a significant change in body weight in the past 3 months (±5% of their body weight) due to bariatric surgery or other conditions\n* taking medication which may affect the study outcomes (i.e. antidiabetic and\u002For cholesterol or lipid-lowering medications and\u002For glucocorticosteroid in supraphysiological doses and\u002For anti-obesity medications)\n* taking regular probiotics and prebiotics (including fruit\u002Fberry polyphenol supplements) in the past 3 months\n* having eating disorders\n* had undergone major surgery 3 months prior to the study or if they had one planned\n* if they had intestinal malabsorption, cirrhosis or chronic kidney disease\n* being pregnant, planning a pregnancy, or breastfeeding.","70 Years",{"count":148,"type":22},73,[53],"The consumption of plant-based foods, particularly berries, has been associated with improved health due to their high content of bioactive compounds. Among these, polyphenols-especially proanthocyanidins (PACs)-may offer protective effects against chronic diseases related to overweight and obesity. Cranberries are naturally rich in PACs and may positively influence metabolic health by modulating the gut microbiota. However, their specific effects on intestinal integrity and broader metabolic outcomes remain underexplored.\n\nThe primary aim of this study is to assess the effects of cranberry supplementation on glucose metabolism, insulin sensitivity, blood lipid levels, and the composition and function of the gut microbiota in overweight and obese individuals.\n\nThis randomized, double-blind, placebo-controlled, crossover clinical trial will include two 12-week intervention periods-one with a cranberry beverage and one with a placebo-separated by a 4-week washout period and preceded by a 2-week lifestyle stabilization phase. Participants will undergo comprehensive metabolic assessments (glucose control, insulin sensitivity, lipid profile), body composition analysis, gut microbiota profiling, and liver fat imaging (MRI in a subsample of female participants). Additional evaluations will include markers of inflammation, appetite regulation, intestinal health, and lifestyle factors.",[56,152,89,153],"Metabolic Syndrome","Microbiota","2026-03-04",{"date":156,"type":33},"2026-03-10",{"date":158,"type":33},"2025-07-07",{"date":160,"type":22},"2026-12",{"name":162,"class":138},"Laval University",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":169,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":175,"conditions":176,"keywords":180,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":41},"100628354","improving-health-among-disadvantaged-girls-to-slow-pubertal-onset-and-reduce-long-term-health-risks-100628354","NCT07460544","Improving Health Among Disadvantaged Girls to Slow Pubertal Onset and Reduce Long-term Health Risks","Inclusion Criteria:\n\n1. Child female biological sex\n2. Child BMI percentile in the overweight\u002Fobese range (BMI percentile ≥85th for age and sex)\n3. Low child household income based on local income requirements for subsidized housing\n4. At least 50% enrollment of child Black or Latina or 'multiple' race or ethnicity identification (self- or mother-identified)\n5. Child between ages 6.5 and 8.0 years at screening\n6. Participation of child with mother who identifies as a primary caregiver\n7. Confirmed child prepubertal status by mother-report on the indicated pubertal staging scale\n8. Child and mother speak English\n9. Successful completion of the 'run-in' protocol, which includes screening and the baseline assessment\n\nExclusion Criteria:\n\n1. Child has medical contraindications to participate in a weight loss program (e.g., chromosomal abnormality, phenylketonuria, syndromal cause of obesity, type 1 diabetes) as determined by child's pediatrician or study pediatrician\n2. Mother has major medical or psychiatric conditions likely to interfere with participation (e.g., dementia, schizophrenia, terminal illness with life expectancy \\\u003C12 months)\n3. Family lives in temporary or group housing or has plans to relocate outside the Seattle metropolitan area in the next 12 months","FEMALE","6 Years","8 Years",{"count":173,"type":22},240,[53],"This study is testing whether improving health in girls during the prepubertal period may slow the onset of puberty. This study will focus on prepubertal girls who have a high weight status (at or above the 85th percentile for body mass index). Half of the girls who join the study will participate in a treatment program to reduce weight and improve lifestyle behaviors, and half of the girls will participate in a control condition. The frequency of pubertal onset will be compared across the groups. This research is important because girls who experience puberty at an earlier age are at risk for poor psychological and physical health.\n\nGirls in the treatment condition will participate in the Family Based Treatment (FBT) program, an established treatment for children who are overweight or obese. Families attend 20 weekly sessions (30 minutes each) over a 5-month period. Sessions are led by a trained interventionist and focus on healthy eating and physical activity behaviors.\n\nGirls in the control condition will receive their usual medical care through their pediatric care doctor or other care provider. Families will also receive educational handouts about 1 time per month, addressing topics related to healthy eating and physical activity behaviors.\n\nFamilies in both the treatment and control conditions will participate in assessments conducted at baseline and approximately 6-, 12-, 18-, 24-, 30-, and 36 months follow-up. These assessments are led by a data collector and include the measurement of height and weight, pubertal status, and health behaviors.",[56,177,178,179],"Puberty","Health Behavior","Cardiometabolic Health",[181,182,183,184,185,186,187,188,189,190,191],"obesity","overweight","puberty","pubertal onset","pubertal development","behavioral intervention","family-based treatment","cardiometabolic health","health behaviors","health behavior change","weight loss","2026-03-03",{"date":156,"type":33},{"date":195,"type":22},"2026-05",{"date":197,"type":22},"2030-06",{"name":199,"class":138},"University of Washington",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":23,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":41},"100622383","phase-1-bioequivalence-study-of-bgm0504-injection-100622383","NCT07382908","Bioequivalence Study of BGM0504 Injection","A Single-Center, Single-Dose, Randomized, Open-Label, Single-Period, Parallel Bioequivalence Study of BGM0504 Injection in Overweight\u002FObese Participants","Inclusion Criteria:\n\n* Age 18-55 years (inclusive).\n* Male weight ≥50 kg, female weight ≥45 kg, and overweight (24.0 ≤ BMI \\\u003C 28.0 kg\u002Fm²) or obese (BMI ≥ 28.0 kg\u002Fm²).\n* From signing the ICF until 3 months after dosing, no pregnancy plan and willing to use effective contraception to avoid pregnancy or causing partner pregnancy, and no plan for sperm\u002Fegg donation.\n* The participant fully understands the trial purpose, nature, methods, and potential adverse reactions, can complete the trial according to the protocol, has good living habits, can maintain good communication with the investigator, and voluntarily signs the ICF.\n\nExclusion Criteria:\n\n* History of severe allergies or severe specific allergic diseases\u002Fhistory (asthma, urticaria, eczematous dermatitis, etc.) or allergic constitution (allergic to two or more foods or drugs), known or suspected allergy to any excipient of BGM0504 Injection.\n* Previous diagnosis of type 1 or type 2 diabetes, or clinically significant abnormal HbA1c at screening.\n* Family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 syndrome.\n* History of acute\u002Fchronic pancreatitis, pancreatic injury, or other high-risk factors for pancreatitis.\n* Past or screening findings of digestive system diseases that may increase participant risk.\n* Positive for HBsAg, HCV antibody, syphilis antibody, or HIV antibody at screening.\n* Participation in any drug or medical device clinical trial and receiving investigational product\u002Fdevice intervention within 3 months prior to screening.\n* Consumption or plan to consume specific foods (including pitaya, mango, grapefruit, pomelo or their juices, high-purine foods like animal organs, seafood, chocolate) or beverages containing caffeine\u002Falcohol within 48 hours before dosing; or unwilling to stop consuming these during the in-house period.\n* Pregnant or breastfeeding women, or positive pregnancy test at screening.\n* Any other condition considered by the investigator as unsuitable for participation or participant withdrawal due to personal reasons..","55 Years",{"count":209,"type":22},144,[25],"This is a study to evaluate the bioequivalence of a single subcutaneous injection of BGM0504 multi-dose pen (experimental formula T1) and BGM0504 single-dose pen (experimental formula T2) with BGM0504 single-dose pen (reference formula R).",[56],"2026-01-26",{"date":215,"type":33},"2026-02-03",{"date":217,"type":33},"2025-12-23",{"date":219,"type":22},"2026-02-12",{"name":221,"class":40},"BrightGene Bio-Medical Technology Co., Ltd.",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":228,"maxAge":49,"enrollmentInfo":229,"targetDuration":4,"studyType":23,"phases":231,"briefSummary":232,"conditions":233,"keywords":238,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":41},"100573937","wearable-technology-data-driven-digital-health-coaching-activation--a-mixed-methods-study-100573937","NCT06752772","WeArable teChnology daTa driVen digitAl healTh cOachINg (ACTIVATION)- A Mixed-methods Study","Inclusion Criteria:\n\n* 21-75 years old\n* Patients who are at risk of any of the following:\n\n  1. Elevated blood pressure\n  2. Overweight (BMI\\>=23kg\u002Fm2)\n  3. Pre-diabetes, OR\n* Patients who have one or more of the following (HOLD) conditions:\n\n  1. Hypertension\n  2. Obesity (BMI\\>=27.5kg\u002Fm2)\n  3. HyperLipidemia\n  4. Type 2 Diabetes Mellitus\n* Patients who own a smartphone\n* Patients who are willing to wear a smartwatch during the intervention period.\n\nExclusion Criteria:\n\n* Patients who have a medical condition that prevented participation in physical activity\n* Patients who have current diagnosis or history of eating disorder, depression\n* Patients who are currently pregnant or planning to become pregnant in the next 6 months\n* Patients who are currently participating in a weight loss programme (commercial, medically supervised, or research study)\n* Patients who are on weight loss medications (over-the-counter or prescription)\n* Patients who are not mentally-, physically- or technologically-capable\n* Patients who is unable to provide informed consent.","21 Years",{"count":230,"type":22},1700,[53],"Public health priorities have shifted towards disease prevention, emphasising health promotion and lifestyle interventions to reduce disease burden. Despite global efforts, the prevalence of chronic diseases remains high, with lifestyle factors such as alcohol consumption, diet, smoking, obesity, and sedentary behaviour playing significant roles. In Singapore, suboptimal lifestyle behaviours are common, contributing to a high incidence of chronic conditions. Metabolic syndrome (MetS), linked to obesity, poses a growing societal burden due to its association with cardiovascular risks. Disparities exist in the delivery of lifestyle interventions among healthcare providers (HCPs), with many patients receiving inadequate guidance. Digital health coaching, incorporating wearable technology, offers promising solutions to bridge these gaps, providing personalised, real-time support and feedback to improve lifestyle behaviours and prevent disease progression. Challenges such as time constraints, lack of feedback, and limited support can be addressed through remote monitoring and tailored interventions, making scalable population-level interventions feasible.",[234,235,56,236,237,88],"Elevated Blood Pressure","Hypertension","Type 2 Diabetes Mellitus (T2DM)","Hyperlipidemia",[239,240,241,242,243],"Digital Health Intervention","Health Coaching","Personalisation","Nudging","Wearables","2025-09-29",{"date":246,"type":33},"2025-10-02",{"date":248,"type":33},"2024-08-06",{"date":250,"type":22},"2026-02",{"name":252,"class":138},"Alexandra Hospital",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":17,"minAge":259,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":269,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":41},"100583995","effect-of-low-valine-diet-on-body-weight-and-metabolic-parameters-100583995","NCT06883578","Effect of Low Valine Diet on Body Weight and Metabolic Parameters","Inclusion Criteria:\n\n* Male or female, 16 years old ≤ age ≤ 80 years old;\n* BMI ≥ 24kg\u002Fm2\n\nExclusion Criteria:\n\n* Excessive drinkers (defined as: in the past 6 months, the weekly alcohol intake of men exceeds 140g, and that of women exceeds 70g);\n* Liver diseases caused by other reasons: such as alcoholic liver disease, acute and chronic viral hepatitis, drug-induced, immune hepatitis (AMA, SMA, ANA), cirrhosis, liver cancer, etc.;\n* Other diseases that affect glucose and lipid metabolism: hyperthyroidism, hypothyroidism, Cushing's syndrome, etc.;\n* Poorly controlled diabetic patients: HbA1c \\>9.5% within three months; or use of hypoglycemic drugs that may affect weight, including pioglitazone, GLP-1, SGLT2 inhibitors;\n* Chronic kidney disease or severe renal impairment, defined as serum creatinine greater than 2.0mg\u002FdL;\n* Serum ALT greater than 3 times the upper limit of normal;\n* Life expectancy of no more than 3 years in the presence of serious health conditions;\n* Those who plan to get pregnant in the near future;\n* Those who cannot participate in the follow-up of the intervention due to other conditions;\n* Continuously used drugs that may cause weight changes for more than 2 weeks in the past year (such as glucocorticoids, thyroid hormones, etc.);\n* Participated in other clinical trials in the past 4 weeks;\n* Those who had gastric volume reduction surgery or digestive tract surgery;\n* Those diagnosed with any tumor disease;\n* Subjects who participated in strenuous exercise or planned to change their diet structure;\n* Unable to sign the informed consent form.","16 Years","80 Years",{"count":262,"type":22},48,[53],"This study aimed to explore the effects of ordinary meal replacements and low-valine meal replacements on the weight and risk of related metabolic diseases in overweight\u002Fobese patients through a randomized double-blind controlled clinical trial.",[266,267,268],"Overweight\u002Fobesity","Metabolic Associated Fatty Liver Disease","Metabolic Diseases",[60,270,271],"Dietary intervention","Low valine meal replacement","2025-03-15",{"date":274,"type":33},"2025-03-19",{"date":276,"type":33},"2025-02-18",{"date":278,"type":22},"2026-04-30",{"name":280,"class":138},"Shanghai Zhongshan Hospital",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":289,"minAge":18,"maxAge":49,"enrollmentInfo":290,"targetDuration":4,"studyType":23,"phases":292,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":41},"100351116","phase-4-effects-of-testosterone-undecanoate-vs-placebo-on-intrahepatic-fat-content-in-overweightobese-men-with-t2dm-or-prediabetes-and-hypogonadism-100351116","NCT03851627","Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight\u002FObese Men With T2DM or Prediabetes and Hypogonadism","52 Week RCT to Investigate the Effect of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese\u002FOverweight Men With T2DM\u002FPrediabetes and Hypogonadism and Subsequent 108 Week Open Label Phase to Investigate Effects on Cardiometabolic Parameters","Test2Func","Inclusion Criteria:\n\n* prediabetes\u002FT2DM\n* male sex\n* HbA1c \\>=5.7% -9.0% or fasting glucose \\>=100mg\u002Fdl or postprandial glucose\\>= 140mg\u002Fdl\n* Age \\>=18 -75 years\n* BMI\\>=25kg\u002Fm²\n* Hypogonadism assessed by laboratory testing (testosterone \\\u003C 4,04ng\u002Fml (=14nmol\u002Fl) Metformin 8 weeks stable dose, SGLT2 inhibitors 3 months stable dose, DPP4 inhibitors 3 months stable dose, GLP1 RA 3 months stable dose and long acting insulin (basal insulin) 8 weeks stable dose\n* able and willing to not change diet and physical activity during enrollment in study\n* consent and able to give informed consent.\n\nExclusion Criteria:\n\n* Current testosterone treatment or testosterone replacement within the last 12 month\n* Serum creatinine\\>1,5mg\u002Fdl\n* Liver enzymes above 3 fold normal range\n* PSA\\>4.0μg\u002Fl\n* Hematocrit\\>50%\n* Known intolerance to testosterone undecanoate or any of its ingredients\n* Myocardial infarction within the last 12month\n* Stroke within the last 12 month\n* Untreated congestive heart disease\n* malignancy within the last 5 years before randomization\n* Prostate cancer or any suspicion thereof\n* Breast cancer\n* Liver tumor\u002Fcancer\n* Epilepsy\n* Migraine\n* Presence of any absolute or relative contraindication for the conduct of an MRI investigation, such as cardiac pacemakers, ferromagnetic haemostatic clips in the central nervous system, metallic splinters in the eye, ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators, cochlear implants, insulin pumps and nerve stimulators, prosthetic heart valves etc.\n* patients on antidiabetic medication like Sulfonylurea or Glitazones.\n* Any other clinical condition that would jeopardize patients safety while participating in this clinical trial\n* Known autoimmune disease or chronic inflammatory condition\n* Other liver disease including chronic viral hepatitis (B or C), alcohol abuse, hemochromatosis, alpha-1 antitrypsin deficiency, autoimmune hepatitis, Wilson's disease, primary sclerosing cholangitis or primary biliary cirrhosis, or liver cirrhosis of any etiology\n* Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake\n* History of bariatric surgery\n* Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight\n* Subjects receiving antihypertensive medication and\u002For thyroid hormones, the dose(s) of which have not been stable for at least 6 weeks prior to baseline\n* Uncontrolled\u002F untreated hypertension\n* Current treatment with systemic steroids at time of informed consent. (Treatment with local and inhaled steroids is allowed)\n* Donation of blood (\\> 400 mL) during the previous 3 months prior to the screening visit or during the duration of the study\n* Participation in another trial with an investigational drug within 30 days prior to informed consent.\n* Pharmacist, study coordinator, other staff thereof, directly involved in the conduct of the protocol.\n* contraindication for intramuscular injection (e.g patient receiving anticoagulants on a regular basis such as NOAKs or VKAs, or DAPT).\n* COPD Gold IV or recurrent acute or allergic asthma (for MPI)\n* Contraindications for cardiac stress test as acute myocardial infarction, instable angina, severe hypertension, myocarditis, life threatening rhythmic disorders without physical activity.","MALE",{"count":291,"type":22},32,[293],"PHASE4","The epidemics of obesity, MeTSy, T2DM and CVD are increasing worldwide. Non-alcoholic fatty liver disease (NAFLD) is becoming recognized as a condition possibly involved in the pathogenesis of these diseases. The prevailing hypothesis for NAFLD pathogenesis is the 'two-hit' model, with insulin resistance and hyperinsulinemia playing essential roles, which have a plethora of effects on hepatic lipid metabolism and can lead to accumulation of triglycerides in hepatocytes. Accepted treatment for NAFLD is lifestyle modifications. Sex hormones might be relevant in T2DM development and treatment. Low testosterone (T) has deteriorating effects on glucose levels, and aggravates in obesity as aromatization of T is enhanced. T deficiency is related to increases of visceral fat accumulation and associated with development of NAFLD. T replacement might be a successful way in hypogonadism to treat obesity and counteract progression of MEtSy,T2DM or CVD driven by visceral fat accumulation or NAFLD.\n\nPrimary Objective To investigate the effects on hepatic lipid content reduction of a therapy with Testosterone undecanoate 1000mg compared to placebo given for 52 weeks in patients with type 2 diabetes mellitus and hypogonadism.",[296,56,297,298],"Fatty Liver","Prediabetes\u002FType2 Diabetes Mellitus","Hypogonadism, Male","2024-03-12",{"date":301,"type":33},"2024-03-13",{"date":303,"type":33},"2022-01-25",{"date":305,"type":22},"2028-12",{"name":307,"class":138},"Alexandra Kautzky-Willer"]